BPS3082 Applied pharmacokinetics, dynamics and product development
The Complete Study & Assessment Guide · Semester 2 2026BPS3082 Overview
- Monash University
- Semester 2 2026
- Level 3 pharmacy
- Quantitative PK and PD
BPS3082 Applied pharmacokinetics, dynamics and product development connects quantitative models to the practical work of developing medicines. The early part builds an evidence foundation through experimental design, statistics, scientific figures and clear reporting.
- Assessed by Examination 30% · Demonstration 10% · Project 45% · Written 15%
- Key terms Experimental Unit, Standard Deviation, Compartment Model, Clearance
- Assessment move Build revision around decisions rather than weeks alone.
- Most asked Are past papers included in the unit materials?
How BPS3082 is assessed
| Component | Weight | Format |
|---|---|---|
| Examination | 30% | Week 9 mid-semester Moodle test: 90 minutes, nine short-answer questions, 72 marks, Weeks 5-8, open access except AI. |
| Demonstration | 10% | Laboratory performance and competency assessed through individual and team practice. |
| Project | 45% | Staged tablet project covering formula and protocol preparation, manufacture, shared data, reporting and problem solving. |
| Written | 15% | Individual PK/PD take-home assignment using modelling software; a nested LMS heading displays 10%, so check the live task page. |
What BPS3082 covers
Follow the unit from experimental evidence through PK and PK/PD models to formulation work, with every chapter built around an applied decision.
Statistical Decisions for Experimental Data
Choose summaries and inferential tests from experimental design, then interpret uncertainty without overstating the result.This chapter turns experimental design into a defensible analysis. It separates independent units from technical repeats, distinguishes SD from SEM, checks normality and equal-variance assumptions, and uses pairing and group count to choose a t-test or ANOVA.
- Experimental units and replication
- Mean, SD and SEM
- Normality and variance assumptions
- Paired and unpaired comparisons
- One-way ANOVA scope
- P-value interpretation
Scientific Figures and Evidence
Turn laboratory observations into honest figures, standalone captions and claims that remain inside the study design.Scientific communication in this unit begins before writing. The research question determines the protocol, the data structure determines the plot, and the plot supports a bounded claim.
- Question-to-figure alignment
- Axes, units and visual scale
- Independent observations
- Standalone captions
- Results paragraph sequence
- Claim boundaries
Compartmental Pharmacokinetic Models
Read concentration-time phases, connect parameters to movement and select a model supported by route and diagnostics.Compartment models summarise kinetic behaviour rather than anatomical rooms. A one-compartment model treats distribution as effectively instantaneous, while a two-compartment model separates a rapidly distributing central space from a slower peripheral space.
- Central and peripheral spaces
- IV bolus profile phases
- Mono-exponential decline
- Bi-exponential decline
- Clearance and volumes
- Model identifiability
Linear and Nonlinear Pharmacokinetics
Diagnose exposure proportionality, saturable processes and Michaelis-Menten behaviour from equations and curves.Linear pharmacokinetics produces dose-proportional exposure over a stated range: doubling dose approximately doubles AUC, and dose-normalised concentration-time profiles remain similar.
- Dose-proportional exposure
- Dose-normalised profiles
- Saturable clearance
- Limited dissolution and absorption
- Vmax and Km
- Michaelis-Menten limiting cases
Variability, Covariates and Precision Dosing
Separate variability layers, screen biologically credible covariates and carry uncertainty into regimen simulations.Population pharmacokinetics treats variability as information rather than a nuisance to be averaged away.
- Interindividual variability
- Within-subject variation
- Residual variability
- Graphical covariate screening
- Biological plausibility
- Population simulation
Direct-Effect PK/PD Models
Interpret Emax, EC50 and Hill effects while checking whether concentration and response are truly immediate.Direct-effect PK/PD models connect concentration to response when there is no meaningful delay between plasma concentration and the observed effect.
- Direct concentration-effect link
- Emax parameter
- EC50 parameter
- Hill coefficient
- Effect-time simulation
- Peak timing check
Model Fitting and Diagnostics
Combine residual plots, predicted-versus-observed checks, AIC and parameter credibility in one selection record.Model fitting is an iterative test of adequacy, not a search for one winning number.
- Predicted-versus-observed plots
- Residual patterns
- Residual sum of squares
- Weighting models
- Akaike Information Criterion
- Parsimony and prediction
Delayed Effects and PBPK
Distinguish distribution delay from biomarker turnover and place physiological modelling in drug development.A delayed effect requires a model that explains what physically or biologically takes time.
- Effect-compartment delay
- Biophase concentration
- Indirect-response turnover
- Input and loss pathways
- Signature profiles
- PBPK development role
Tablet Formulation and Laboratory Quality
Scale a formula, write a reproducible protocol, preserve the batch record and interpret product tests carefully.The formulation block converts a quantitative formula into a controlled laboratory process and an auditable development argument.
- Tablet formula scaling
- Ingredient functions
- Protocol construction
- GMP batch records
- Tablet performance tests
- Laboratory reporting
The middle of the unit moves through compartmental pharmacokinetics, linear and nonlinear exposure, interindividual variability, covariates, direct concentration-effect models, delayed responses and model diagnostics. The laboratory block then turns a tablet formula into a protocol, a manufactured batch, quality-test data and a scientific report.
The difficulty comes from changing representations.
A student may need to move from a concentration-time curve to a compartment model, from an AUC-dose relationship to a saturable mechanism, or from a scatter plot to a biologically plausible covariate. Calculations matter, but the published learning outcomes repeatedly require selection, interpretation, simulation and recommendation.
Strong answers therefore show the equation or visual signature and explain what it means for a model, regimen or product decision.
The published assessment structure has four components: an Examination worth 30%, a Demonstration worth 10%, a Project worth 45%, and a Written component worth 15%. The Examination is explicitly a Week 9 mid-semester test rather than an end-of-semester assessment.
It lasts 90 minutes, contains nine short-answer questions worth 72 marks, covers Weeks 5-8 and is open access except for AI. The project is staged across formula and protocol preparation, laboratory performance, a GMP-style batch record, shared data, a laboratory report and a problem-solving analysis. This guide mirrors those decisions with original practice rather than reproducing any assessment prompt.
Worked example · free
Interpret nonlinear exposure before naming the mechanism
- +2Dose doubled, while AUC increased by 112 ÷ 42 = 2.67-fold, so exposure rose more than proportionally.
- +2Saturable metabolism or excretion is plausible because effective clearance can fall as an eliminating pathway approaches capacity.
- +2Compare dose-normalised profiles and examine clearance or metabolite evidence before assigning the responsible pathway.
Key terms
- Experimental Unit
- The independent object assigned to a condition or treatment, which determines the real sample size.
- Standard Deviation
- A measure of spread among observed values rather than uncertainty in the estimated mean.
- Compartment Model
- A mathematical representation grouping tissues with sufficiently similar kinetic behaviour.
- Clearance
- The proportionality term relating elimination rate to concentration under the stated pharmacokinetic model.
- Central Compartment
- The rapidly distributing model space containing plasma and tissues treated as equilibrating quickly.
- Peripheral Compartment
- A model space representing tissues that exchange drug more slowly with the central compartment.
- Michaelis-Menten Kinetics
- A saturable rate relationship determined by maximum capacity and the half-capacity concentration.
- Interindividual Variability
- Variation in model parameters between different people in a population.
- Covariate
- A measured characteristic used to explain a biologically credible part of parameter variability.
- Emax
- The modelled maximum response in a concentration-effect relationship.
- EC50
- The concentration producing half of Emax under the fitted response model.
- Indirect Response
- A delayed-effect structure where drug changes production or loss of an endogenous response.
- Batch Record
- A contemporaneous account of actual materials, actions, observations and deviations during manufacture.
BPS3082 FAQ
How hard is this unit in practice?
The challenge is the movement between graphs, equations and decisions. Students must recognise a profile, choose a model, interpret its parameters and explain the consequence for dosing or development. The source provides no pass-rate or difficulty rating, so the useful preparation is repeated short-answer practice that makes each reasoning link explicit.
Is there an end-of-semester test?
The published assessment structure shows no end-of-semester test. Its Examination component is a Week 9 mid-semester Moodle test worth 30%. The task is 90 minutes with nine short-answer questions worth 72 marks and covers Weeks 5-8. Check the live Moodle task for any updated operational instruction before test day.
What materials are allowed in the timed test?
The captured task description says the mid-semester test is open access and permits online or printed materials, but not AI. It also requires attendance and the student’s own computer. Prepare a searchable index rather than a large unstructured folder, and follow the current Moodle instructions if they differ.
What does the project assess?
The 45% project combines tablet formula calculation, protocol construction, manufacture, a GMP-style batch record, shared laboratory data, reporting and a problem-solving analysis. The work is team based with individual contribution considered, so accurate handoffs, contemporaneous records and transparent data analysis are as important as the final report.
Do I need to calculate PK and PD models?
Yes, the unit contains real quantitative work, including compartmental parameters, Michaelis-Menten kinetics, Emax relationships, simulations and statistical analysis. Calculations should always end with interpretation: what the result says about exposure, response, variability, model choice or regimen design.
Are past papers included in the unit materials?
The captured folder contains lecture, workshop, revision and feedback materials but no identifiable past paper, sample final or practice final. This guide therefore uses original questions modelled on the published short-answer skills and source-supported question types, without copying or lightly rewording course assessment prompts.
Questions students ask in each BPS3082 chapter
- When should I use a paired comparison?
- Use a paired method when each value in one condition has a meaningful match in the other, such as the same tablet measured before and after storage. Analyse within-pair changes and check their assumptions rather than treating all measurements as independent. Record what creates the pairing so the design remains visible. Chapter 01 · Statistical Decisions for Experimental Data
- What information belongs in a figure caption?
- Identify the outcome, groups, units, independent sample size, visual symbols, error-bar meaning and analysis where comparison symbols appear. A reader should not need the surrounding paragraph to decode the main evidence. Define any transformation or normalisation that changes the plotted scale. Chapter 02 · Scientific Figures and Evidence
- Does a two-compartment model mean two organs?
- No. Compartments group tissues with similar kinetic behaviour. The central and peripheral spaces are mathematical representations, and their number is inferred from the concentration-time profile rather than counted from anatomy. A model can represent many tissues with only a few kinetic spaces. Chapter 03 · Compartmental Pharmacokinetic Models
- What does greater-than-proportional AUC suggest?
- It suggests effective clearance may be falling as dose rises, which can occur when metabolism or excretion approaches capacity. The curve direction is only a clue: confirm that the doses and AUC values are comparable, examine dose-normalised profiles, and seek pathway evidence before naming a mechanism. State the studied range because the same compound may appear linear at lower doses. Chapter 04 · Linear and Nonlinear Pharmacokinetics
- Is a strong correlation enough to include a covariate?
- No. The relationship also needs biological plausibility, a sensible link to a model parameter, stable estimation and evidence that it improves explanation or prediction. Chance, confounding, a narrow sampled range or one influential observation can produce an impressive trend. Describe the plot, state the mechanism, test the model and check what variability remains. Chapter 05 · Variability, Covariates and Precision Dosing
- What is the difference between Emax and EC50?
- Emax sets the response plateau, while EC50 locates the concentration giving half of that plateau. Lower EC50 shifts the curve left without necessarily changing the maximum. Their units also differ: Emax carries response units and EC50 carries concentration units. Estimate interpretation should be limited when the observed data do not cover both the rising region and plateau. Chapter 06 · Direct-Effect PK/PD Models
- Is the model with the lowest AIC always best?
- No. AIC is a relative comparison on the same data and likelihood basis. Residual patterns, parameter stability, mechanism and intended prediction also matter, especially when AIC differences are small. A candidate with slightly lower AIC but ordered residual bias is not automatically more adequate; investigate the missed structure and repeat the full comparison. Chapter 07 · Model Fitting and Diagnostics
- What causes delay in an effect-compartment model?
- The delay represents time needed for drug to equilibrate from plasma to the action site. The response model is driven by effect-site concentration rather than immediate plasma concentration. Check peak timing, hysteresis and whether the equilibration parameter is supported by sufficiently dense concentration and response sampling. Chapter 08 · Delayed Effects and PBPK
- Why must ingredient masses sum to the batch total?
- The mass-balance check confirms that percentages, units and process allowance were applied from one common basis. A mismatch reveals a calculation, conversion or rounding error before manufacture begins. Keep adequate precision until weighing, show the total row and distinguish extra batch material from a change in each tablet's intended dose. Chapter 09 · Tablet Formulation and Laboratory Quality
How to prepare for the assessments
Build revision around decisions rather than weeks alone. First, keep a one-page map of visual signatures: mono- versus bi-exponential decline, proportional versus nonlinear AUC-dose behaviour, Emax curve shifts, direct versus delayed effect, and residual patterns. Second, attach each equation to parameter meanings and units; a correct substitution without interpretation is incomplete.
Third, practise the published short-answer format by giving one observation, one mechanism and one limitation or diagnostic. Fourth, index permitted notes so the Week 9 open-access test does not become a search exercise. For the project, reconcile the formula, protocol, batch record, shared data and report as one evidence chain. Record actual laboratory actions and deviations contemporaneously.
Finally, revisit covariate reasoning across chapters: a visible association needs biological plausibility, and a useful relationship still leaves residual variability. That habit protects both modelling and product-development conclusions from overclaiming.
